HIGHLIGHTS
- who: BCR/ABL and colleagues from the Faculty of Biology and Environmental Protection, Department of Molecular Genetics, University of Lodz, u0141u00f3du017a, Poland have published the article: Role of anti-apoptotic pathways activated by BCR/ABL in the resistance of chronic myeloid leukemia cells to tyrosine kinase inhibitors, in the Journal: (JOURNAL)
- what: This study demonstrated that inhibition of JAK1/2 improved the antitumor activity of two myeloma therapies, melphalan and bortezomib in_vivo.
- how: Randomized study was conducted in chronic phase CML patients resistant to IFN-u03b1 or intolerant to therapy with this agent . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.